Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.47 - $0.76 $12,753 - $20,623
27,136 New
27,136 $12,000
Q4 2023

Feb 14, 2024

BUY
$0.52 - $0.78 $50,402 - $75,603
96,927 New
96,927 $69,000

Others Institutions Holding GLTO

About Galecto, Inc.


  • Ticker GLTO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,395,700
  • Market Cap $172M
  • Description
  • Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...
More about GLTO
Track This Portfolio

Track Two Sigma Securities, LLC Portfolio

Follow Two Sigma Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Securities, LLC with notifications on news.